1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Coherus Delivers With Pegfilgrastim Autoinjector Launch

New Version Of Udenyca US Neulasta Biosimilar Comes Ahead Of On-Body Device

 
• By Dave Wallace

Amid increasing competition on biosimilar pegfilgrastim in the US, Coherus is looking to bolster its position with the launch of an Udenyca autoinjector presentation, while it awaits approval for a rival to Amgen’s Neulasta Onpro on-body injector device later this year.

A red hot air balloon standing out in a sea of white hot air balloons
Coherus is looking to stand out among a host of pegfilgrastim biosimilars • Source: Shutterstock

Coherus BioSciences has delivered on the first part of a plan to differentiate itself from rival pegfilgrastim biosimilars in the US by launching an autoinjector version of its existing Udenyca (pegfilgrastim-cbqv) rival to Neulasta.

Billed as Udenyca AI, the biosimilar is described by Coherus as “the only pegfilgrastim prefilled autoinjector product presentation available in the US that can be administered either in-office or at-home,” meeting what the firm calls a “high unmet need by giving providers

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products